-transparent.png){kind=logo}
Normal platelet function depends, in part, on platelet PG synthesis. PG synthetase (cyclo-oxygenase) catalyzes the first step in PG synthesis, the formation of PGH2 from arachidonic acid. Inhibition of the enzyme by ASA results in an abnormality in the platelet release reaction. Patients with apparent congenital abnormalities in the enzyme have been described, and the defects have been referred to as "aspirin-like" defects of platelet function. These patients lack platelet PG synthetase activity, but the actual content of PG synthetase protein in these individuals' platelets is unknown. Therefore an RIA for human platelet PG synthetase would provide new information, useful in assessing the aspirin-like defects of platelet function. An RIA for human platelet PG synthetase is described. The assay utilizes a rabbit antibody directed against the enzyme is assayed by its ability to inhibit precipitation of the [125I]antigen. The assay is sensitive to 1 ng of enzyme. By the immune assay, human platelets contain approximately 1200 ng of PG synthetase protein per 1.5 mg of platelet protein (approximately 10(9) platelets). This content corresponds to 10,000 enzyme molecules per platelet. The assay provides a rapid and convenient assay for the human platelet enzyme, and it can be applied to the assessment of patients with apparent platelet PG synthetase (cyclo-oxygenase) deficiency.
G J Roth, and
E T Machuga
September 1973,
Prostaglandins,
G J Roth, and
E T Machuga
October 1974,
Cancer,
G J Roth, and
E T Machuga
October 1977,
Annals of the rheumatic diseases,
G J Roth, and
E T Machuga
January 1977,
Biochimie,
G J Roth, and
E T Machuga
July 1974,
Prostaglandins,
G J Roth, and
E T Machuga
February 1978,
The Journal of clinical investigation,
G J Roth, and
E T Machuga
March 1972,
Immunochemistry,
G J Roth, and
E T Machuga
June 1971,
Biochemistry,
G J Roth, and
E T Machuga
October 1972,
Science (New York, N.Y.),
